公开(公告)号：US20230302132A1

公开(公告)日：2023-09-28

申请号：US18041536

申请日：2020-08-14

申请人： SHANGHAI XINGHUA BIO PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD

发明人： Hua LIU

IPC分类号： A61K39/00 ,  C07K14/42 ,  A61K39/39 ,  C07K14/55 ,  C12N5/0783

CPC分类号： A61K39/4611 ,  A61K39/4635 ,  A61K39/4637 ,  C07K14/42 ,  A61K39/39 ,  C07K14/55 ,  C12N5/0638 ,  A61K2239/39 ,  C12N2501/2302 ,  C12N2501/24 ,  C12N2501/59

摘要： Provided are a simple and convenient method for preparing universal immune cells and the use thereof. The method comprises placing allogeneic immune cells and specific cell mitogens, cytokines, and immunologic adjuvants in a liquid cell culture medium to be co-cultured in a culture container, so as to obtain a universal immune cell culture with a high immunocompetence. Many clinical long-term practical applications have proven that the universal immune cells are safe and reliable, durable and effective, and have no rejection reaction. Therefore, the universal immune cells can be used as maternal cells of other types of universal immune cell preparations, such as CAR-T and TCR-T, and can be used in fields including adoptive cellular immunotherapy, etc.

公开(公告)号：US20230242875A1

公开(公告)日：2023-08-03

申请号：US17920373

申请日：2021-04-14

申请人： RUICHUANG BIOTECH.CO., LTD.

发明人： Liming Yang ,  Zhiqiang Xiang ,  Qinghua Sun

IPC分类号： C12N5/078 ,  A61K35/17

CPC分类号： C12N5/0634 ,  A61K35/17 ,  C12N2501/515 ,  C12N2501/59 ,  C12N2500/90 ,  C12N2509/00 ,  C12N2501/2302

摘要： The present invention relates to a universal-type efficient in-vitro amplification method for multiple times of clinical feedback of allogenic DNT cells. In the method of the present invention, the amount of a T cell activator is phased down in a continuous culture process without the need for additional interleukin-4 or AB serum.

公开(公告)号：US11649437B2

公开(公告)日：2023-05-16

申请号：US17152149

申请日：2021-01-19

申请人： CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Catherine M. Bollard ,  Conrad Russell Cruz ,  Patrick J. Hanley ,  Michael Keller

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61P31/00 ,  A61P37/04 ,  A61P15/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/73 ,  C07K14/705

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61P15/00 ,  A61P31/00 ,  A61P37/04 ,  C07K14/5412 ,  C07K14/5418 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/59 ,  C12N2502/1121 ,  C12N2502/1157

摘要： Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.

公开(公告)号：US20180155690A1

公开(公告)日：2018-06-07

申请号：US15822843

申请日：2017-11-27

申请人： KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES

发明人： You-Soo Park ,  Cheol-Hun Son ,  Kwangmo Yang

IPC分类号： C12N5/0783 ,  C12N13/00 ,  A61K35/17 ,  A61P35/00

CPC分类号： C12N5/0646 ,  A61K35/17 ,  A61K2035/124 ,  A61P35/00 ,  C12N13/00 ,  C12N2501/59 ,  C12N2501/599 ,  C12N2502/11 ,  C12N2502/1157 ,  C12N2502/1164

摘要： Provided is a method for preparing natural killer cell with high efficiency using irradiated peripheral blood mononuclear cells, more particularly to a method for proliferating highly activated NK cells using a combination of irradiated peripheral blood mononuclear cells (PBMCs) and a CD16 antibody and an anti-cancer cell therapeutic composition containing the natural killer cells (NK cells) prepared thereby. Further provided is a method for large-scale proliferation of activated NK cells with high efficiency using a combination of irradiated peripheral blood mononuclear cells (PBMCs) and a CD16 antibody without the use of cancer cells or genetically modified feeder cells having safety issues as feeder cells. The highly purified and highly cytotoxic NK cells proliferated in large quantities can be used as an active ingredient of a cancer immunotherapeutic composition.

公开(公告)号：US20170216356A1

公开(公告)日：2017-08-03

申请号：US15432534

申请日：2017-02-14

申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.

发明人： Zelig ESHHAR ,  Assaf MARCUS ,  Tova WAKS

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61K31/137 ,  C07K16/32 ,  A61K31/675

CPC分类号： A61K35/17 ,  A61K31/135 ,  A61K31/137 ,  A61K31/185 ,  A61K31/196 ,  A61K31/197 ,  A61K31/4245 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/39541 ,  A61K47/6891 ,  A61K48/00 ,  A61K2035/124 ,  A61N5/10 ,  B82Y5/00 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/732 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/59 ,  C12N2501/599 ,  C12N2510/00

摘要： A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

公开(公告)号：US20170010282A1

公开(公告)日：2017-01-12

申请号：US15217251

申请日：2016-07-22

申请人： GALPHARMA CO., LTD.

发明人： Mitsuomi HIRASHIMA ,  Toshiro NIKI ,  Tomohiro ARIKAWA ,  Souichi OOMIZU ,  Takeshi KADOWAKI

IPC分类号： G01N33/68 ,  A61K38/17 ,  C12N5/0783 ,  G01N33/569 ,  C12N5/0784 ,  C12N5/0786 ,  G01N33/50 ,  C07K14/47 ,  C12N5/0781

CPC分类号： G01N33/6893 ,  A61K35/17 ,  A61K38/1732 ,  A61K49/0004 ,  C07K14/4726 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0639 ,  C12N5/0645 ,  C12N5/0646 ,  C12N2501/59 ,  G01N33/5094 ,  G01N33/56972 ,  G01N33/68 ,  G01N2333/42 ,  G01N2333/4724 ,  G01N2333/705

摘要： The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface.

摘要翻译： 本发明的目的是提供一种可以显示基于半乳凝素-9的生理活性的细胞，细胞的制造方法和细胞的使用。 为了实现上述目的，本发明的细胞含有半乳凝素-9，半乳凝素-9在细胞表面表达。

公开(公告)号：US09394525B2

公开(公告)日：2016-07-19

申请号：US14684252

申请日：2015-04-10

申请人： Thiru Venkat Gopal

发明人： Thiru Venkat Gopal

IPC分类号： C12N5/00 ,  C12N5/26 ,  C12N5/16 ,  C12N5/0793

CPC分类号： C12N5/0619 ,  C12N5/0691 ,  C12N5/16 ,  C12N5/166 ,  C12N2500/46 ,  C12N2501/06 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/59 ,  C12N2501/73 ,  C12N2501/998 ,  C12N2506/00 ,  C12N2506/30

摘要： Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient.

公开(公告)号：US09029141B2

公开(公告)日：2015-05-12

申请号：US13064782

申请日：2011-04-14

申请人： Thiru V. Gopal

发明人： Thiru V. Gopal

IPC分类号： C12N5/00 ,  C12N5/0793 ,  C12N5/16

CPC分类号： C12N5/0619 ,  C12N5/0691 ,  C12N5/16 ,  C12N5/166 ,  C12N2500/46 ,  C12N2501/06 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/59 ,  C12N2501/73 ,  C12N2501/998 ,  C12N2506/00 ,  C12N2506/30

摘要： Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient.

摘要翻译： 公开哺乳动物细胞质供体细胞系。 患者特异性细胞系的披露。 通过融合分化的哺乳动物细胞和功能去核的哺乳动物胚胎细胞系获得哺乳动物细胞质供体细胞系的方法。 通过融合分化的哺乳动物细胞和功能去核的人类癌细胞获得哺乳动物细胞质供体细胞系的方法。 通过功能性去除哺乳动物细胞质供体细胞系并将功能性去核的哺乳动物细胞质供体细胞系与从患者获得的分化细胞融合来获得类似于哺乳动物细胞质供体细胞系的细胞类型的患者特异性细胞系的方法。 一种通过向患者施用患者特异性细胞系来治疗人类患者的方法。

公开(公告)号：US20140286915A1

公开(公告)日：2014-09-25

申请号：US14346160

申请日：2012-09-21

申请人： CYTOMATRIX PTY LTD

发明人： Melinda L. Tursky ,  Mark A. Kirkland

IPC分类号： C12N5/0789

CPC分类号： C12N5/0647 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/59 ,  C12N2501/998

摘要： The present invention relates to hematopoietic cells, and more specifically to methods for long-term in vitro culturing and ex vivo expansion of hematopoietic cells. The present invention also provides compositions useful for culturing cells, such as media for culturing hematopoietic cells, specifically haematopoietic stem cells (HSC) and haematopoietic progenitor cells (HPC). The present invention further provides compositions including growth factor combinations and methods utilising altered growth and environmental conditions that are applicable in vitro culturing and to ex vivo expansion of HSC and/or HPC.

摘要翻译： 本发明涉及造血细胞，更具体地涉及造血细胞的长期体外培养和离体扩增的方法。 本发明还提供了用于培养细胞的组合物，例如用于培养造血细胞的培养基，特别是造血干细胞（HSC）和造血祖细胞（HPC）。 本发明还提供包含生长因子组合的组合物和利用可用于HSC和/或HPC的体外培养和体外扩增的改变的生长和环境条件的方法。

公开(公告)号：US20120148553A1

公开(公告)日：2012-06-14

申请号：US13182250

申请日：2011-07-13

申请人： Robert J. HARIRI ,  Mohammad A. Heidaran ,  Stephen Jasko ,  Lin Kang ,  Eric Law ,  Ajai Pal ,  Bhavani Stout ,  Vanessa Voskinarian-Berse ,  Andrew Zeitlin ,  Xiaokui Zhang

发明人： Robert J. HARIRI ,  Mohammad A. Heidaran ,  Stephen Jasko ,  Lin Kang ,  Eric Law ,  Ajai Pal ,  Bhavani Stout ,  Vanessa Voskinarian-Berse ,  Andrew Zeitlin ,  Xiaokui Zhang

IPC分类号： A61K35/14 ,  A61P35/02 ,  A61P35/00 ,  C12N5/0783 ,  C12N5/09

CPC分类号： C12N5/0646 ,  A61K35/17 ,  A61K2035/124 ,  C12N2500/05 ,  C12N2500/25 ,  C12N2500/33 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2500/46 ,  C12N2500/84 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2302 ,  C12N2501/2303 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/59 ,  C12N2501/91 ,  C12N2501/998 ,  C12N2506/11

摘要： Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

摘要翻译： 本文提供了使用两步膨胀和分化方法生产天然杀伤细胞的方法。 本文还提供了抑制肿瘤细胞增殖，治疗患有癌症或病毒感染的个体的方法，包括将通过该方法产生的NK细胞施用于具有癌症或病毒感染的个体。